As of November 6, 2026, Adicet Bio, Inc. is a publicly traded company (Nasdaq: ACET). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 8.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include RA Capital (9.9%), Franklin Templeton, Inc. (7.7%), Franklin Resources, Inc. (6.5%) (Schedule 13D/A, April 10, 2026).
Is this your company?
About to sign with, pay or invest in Adicet Bio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Adicet Bio, Inc. a real, registered company?
- Adicet Bio, Inc. files with the SEC under CIK 1720580 (its SEC filings).
- Its shares are listed under the ticker ACET on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Adicet Bio, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Franklin Templeton, Inc. (filed 2026-10-28).
Who are Adicet Bio, Inc.'s owners and officers?
Adicet Bio, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-28 | Franklin Templeton, Inc. | 7.7% |
| Schedule 13G, 2026-10-23 | Zedek Daniel Clayton | 5.4% |
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-05-15 | Woodline Partners LP | 3.3% |
| Schedule 13G/A, 2026-04-13 | Ra Capital Management, L.P. | 12.3% |
| Schedule 13D/A, 2026-04-10 | Orbimed Advisors LLC | 8.8% |
| Schedule 13G, 2026-02-17 | Woodline Partners LP | 6.5% |
| Schedule 13G/A, 2026-02-17 | Tang Capital Management, LLC | 0.1% |
| Schedule 13G/A, 2026-02-17 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G, 2026-01-29 | Franklin Resources, Inc. | 6.5% |
| Schedule 13D/A, 2025-10-10 | Orbimed Advisors LLC | 9.6% |
Questions about who owns Adicet Bio, Inc.
Who owns Adicet Bio, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Adicet Bio, Inc.: Ra Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Orbimed Advisors LLC (8.8%, Schedule 13D/A, filed 2026-04-10), Franklin Templeton, Inc. (7.7%, Schedule 13G/A, filed 2026-10-28), Franklin Resources, Inc. (6.5%, Schedule 13G, filed 2026-01-29) and Zedek Daniel Clayton (5.4%, Schedule 13G, filed 2026-10-23).
Who are the largest shareholders of Adicet Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of Adicet Bio, Inc. on this page are Ra Capital Management, L.P. (9.9%), Orbimed Advisors LLC (8.8%) and Franklin Templeton, Inc. (7.7%).
When did Ra Capital Management, L.P. buy into Adicet Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Adicet Bio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Adicet Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Adicet Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Adicet Bio, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- RA Capital Healthcare Fund LP, a 10% owner: 932,624 shares (10.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-29).
- , a 10% owner: 932,624 shares (10.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-29).
- , a 10% owner: 932,624 shares (10.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-29).
- RA Capital, a 10% owner: 932,624 shares (10.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-29).
- , a director: 108,566 shares (1.2% of shares outstanding) (Form 4, 2025-06-13).
Shares outstanding: 9,361,596 as of 2026-11-03, from the company's latest SEC cover page.
How much has Adicet Bio, Inc. raised?
No fundraising or offering filing from Adicet Bio, Inc. is on file with us.
Keep reading
More on Adicet Bio, Inc. and the records around it.
Adicet Bio, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/adicet-bio